Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Center for New Medical Technologies, Novosibirsk, Russia | OTHER |
| I.M. Sechenov First Moscow State Medical University | OTHER |
| University of Rochester | OTHER |
Not provided
Not provided
Not provided
Not provided
A retrospective analysis
4200 EMR of patients at high risk for stroke with 1-year follow-up will be enrolled in the current study and analyzed by clinical decision support systems (CDSS MedicBK) utilizing a core laboratory.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| CDSS (MedicBK) Analysis |
| ||
| Core Laboratory Analysis |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| anticoagulation treatment | Drug | Adherence to personalized evidence-based anticoagulant treatment in patients at high risk for stroke with atrial fibrillation |
|
| Measure | Description | Time Frame |
|---|---|---|
| The percentage of guideline-based and personalized EBM recommendations | The percentage of guideline-based and personalized EBM recommendations acted on by clinicians for anticoagulant therapy in patients with AF. All discrepancies between routine and CDSS-recommended treatment resulting in frame of guideline-based therapy and personalized EBM therapy will be adjudicated by core laboratory. | 1-year |
| Measure | Description | Time Frame |
|---|---|---|
| Quantify the performance of the CDSS (MedicBK) algorithm | Quantify the performance of the CDSS (MedicBK) algorithm for presents treatment suggestions in frame of guideline-based therapy and personalized EBM therapy: the sensitivity, specificity, NPV, and PPV | 1-year |
| 1-year FU outcomes |
Not provided
Inclusion Criteria:
EMR only if an ECG diagnosis (12-lead ECG, 24-h Holter, or other electrocardiographic documentation) confirming AF was made in patients at high risk for stroke by CHA2DS2-VASc (≥2 in men and ≥3 in women).
Exclusion Criteria:
No
Not provided
Not provided
Not provided
Not provided
Patients at high risk for stroke with atrial fibrillation
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Evgeny Pokushalov, Prof. MD PhD | Center for New Medical Technologies, Novosibirsk, Russia | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Evgeny Pokushalov | Novosibirsk | 630090 | Russia |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001281 | Atrial Fibrillation |
| D020521 | Stroke |
| ID | Term |
|---|---|
| D001145 | Arrhythmias, Cardiac |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D010335 | Pathologic Processes |
Not provided
Not provided
| Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health |
| OTHER |
Not provided
Not provided
Not provided
Outcomes for all-cause mortality, thromboembolism (TE), bleeding, and the composite endpoint of any thromboembolism, cardiovascular death, or bleeding in relation to whether they were guideline-based treatment or personalized EBM treatment. Thromboembolism refers to stroke, transient ischemic attack, acute coronary syndrome, coronary intervention, cardiac arrest, peripheral embolism, and pulmonary embolism |
| 1-year |
| Predictors | Predictors of guideline-based and personalized EBM adherence | 1-year |
| D013568 |
| Pathological Conditions, Signs and Symptoms |
| D002561 | Cerebrovascular Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D014652 | Vascular Diseases |